Suchergebnisse - "Engelhardt, Monika"

PubPharm (15)

1

Pomalidomide combinations are a safe and effective option after daratumumab failure

enthalten in: Journal of cancer research and clinical oncology | 2023

von Brioli, A. | Gengenbach, L. | Mancuso, K. | +9

2

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

3

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Dimopoulos, M. | Terpos, E. | Boccadoro, M. | +72

4

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

5

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma : a first-in-human, multicentre, phase 1-2a trial

enthalten in: The Lancet. Haematology | 2020

von Raab, M. | Engelhardt, M. | Blank, A. | +15

6

Carfilzomib combination treatment as first-line therapy in multiple myeloma : where do we go from the Carthadex (KTd)-trial update?

enthalten in: Haematologica | 2019

von Engelhardt, M. | Yong, K. | Bringhen, S. | +1

CommentOn: Haematologica. 2019 Nov;104(11):2265-2273. - PMID 30948492

7

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Mateos, M. | Blacklock, H. | Schjesvold, F. | +119

CommentIn: Ann Transl Med. 2020 Jun;8(12):777. - PMID 32647702

8

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404

9

enthalten in: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer | 2018

von Engelhardt, M. | Ajayi, S. | Reinhardt, H. | +3

10

The Changing Landscape of Smoldering Multiple Myeloma : A European Perspective

enthalten in: The oncologist | 2016

von Caers, J. | Fernández de Larrea, C. | Leleu, X. | +13